- Home
- SGD vs TOVX Comparison
SGD vs TOVX Comparison
Compare SGD & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- TOVX
- Stock Information
- Founded
- SGD 2021
- TOVX 2001
- Country
- SGD United States
- TOVX United States
- Employees
- SGD N/A
- TOVX N/A
- Industry
- SGD
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SGD
- TOVX Health Care
- Exchange
- SGD Nasdaq
- TOVX Nasdaq
- Market Cap
- SGD 4.4M
- TOVX 3.8M
- IPO Year
- SGD N/A
- TOVX 2006
- Fundamental
- Price
- SGD $0.99
- TOVX $0.27
- Analyst Decision
- SGD
- TOVX Hold
- Analyst Count
- SGD 0
- TOVX 1
- Target Price
- SGD N/A
- TOVX N/A
- AVG Volume (30 Days)
- SGD 446.1K
- TOVX 44.2M
- Earning Date
- SGD 11-14-2025
- TOVX 11-11-2025
- Dividend Yield
- SGD N/A
- TOVX N/A
- EPS Growth
- SGD N/A
- TOVX N/A
- EPS
- SGD N/A
- TOVX N/A
- Revenue
- SGD $1,536,255.00
- TOVX N/A
- Revenue This Year
- SGD N/A
- TOVX N/A
- Revenue Next Year
- SGD N/A
- TOVX N/A
- P/E Ratio
- SGD N/A
- TOVX N/A
- Revenue Growth
- SGD 1570.24
- TOVX N/A
- 52 Week Low
- SGD $0.65
- TOVX $0.26
- 52 Week High
- SGD $3.27
- TOVX $2.08
- Technical
- Relative Strength Index (RSI)
- SGD 44.98
- TOVX 41.23
- Support Level
- SGD $0.91
- TOVX $0.26
- Resistance Level
- SGD $1.09
- TOVX $0.29
- Average True Range (ATR)
- SGD 0.10
- TOVX 0.06
- MACD
- SGD 0.00
- TOVX -0.00
- Stochastic Oscillator
- SGD 60.47
- TOVX 2.19
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.